Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasms 30Prostatic Neoplasms 22Neoplasm Metastasis 20Breast Neoplasms 17Lung Neoplasms 16Colorectal Neoplasms 15Leukemia, Myeloid, Acute 14Pancreatic Neoplasms 13Ovarian Neoplasms 12Urinary Bladder Neoplasms 11Lymphoma 11Hematologic Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Myelodysplastic Syndromes 9Squamous Cell Carcinoma of Head and Neck 8Sarcoma, Kaposi 8Pheochromocytoma 8Multiple Myeloma 8Melanoma 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Neuroendocrine Tumors 7Mouth Neoplasms 7Kidney Neoplasms 7Glioma 7Thyroid Neoplasms 6

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NIH × Sinonasal undifferentiated carcinoma × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡